Logo do repositório
 
Publicação

Reporting of participant race and ethnicity from COVID-19 randomized controlled drug and biologicals trials: a scoping review

2024-11-28Artigo científico Acesso restrito
Ver registo simples
datacite.subject.sdg03:Saúde de Qualidade
datacite.subject.sdg10:Reduzir as Desigualdades
datacite.subject.sdg09:Indústria, Inovação e Infraestruturas
dc.contributor.authorPranić, Shelly Melissa
dc.contributor.authorEstêvão, Maria Dulce da Mota Antunes de Oliveira
dc.contributor.authorVasanthan, Lenny T
dc.contributor.authorPérez-Neri, Iván
dc.contributor.authorPulumati, Anika
dc.contributor.authorJunior, Fábio Antonio Serra de Lima
dc.contributor.authorMalih, Narges
dc.contributor.authorMishra, Vinayak
dc.contributor.authorThompson, Jacqueline
dc.contributor.authorNnate, Daniel
dc.date.accessioned2026-04-29T16:49:05Z
dc.date.available2026-04-29T16:49:05Z
dc.date.issued2024-11-28
dc.description.abstractRacial and ethnic minorities have been disproportionally burdened by hospitalization and death due to COVID-19. Participation of individuals of diverse races and ethnicities in clinical trials, according to study-level characteristics of randomized controlled trials (RCTs) that test effectiveness of COVID-19 drugs, could be insightful for future researchers. Our objective for this scoping review was to describe the frequency of race and ethnicity reported as demographic variables and specific reporting of race and ethnicity according to COVID-19 RCT characteristics. We conducted comprehensive searches in PubMed, ProQuest, World Health Organization Database, and Cochrane Central Register of Controlled Trials, and gray literature via preprint servers from January 1, 2020, to May 4, 2022. We included RCTs on emergency- or conditionally approved COVID-19 drug interventions (remdesivir, baricitinib, and molnupiravir) with or without comparators. Self-reported race as American Indian/Pacific Islander, Asian, Black/African American, or White, ethnicity as Hispanic/Latinx, study design characteristics, and participant-relevant data were collected. In total, 17 RCTs with 17 935 participants were included. Most (n = 13; 76%) reported at least 1 race and ethnicity and were US-based, industry-funded RCTs. Asian, Black, Latinx, and White participants were mostly enrolled in RCTs that studied remdesivir. Native American and Hawaiian participants were mostly assessed for progression to high-f low oxygen/noninvasive ventilation. Time to recovery was assessed predominantly in Black and White participants, whereas hospitalization or death was mostly assessed in Asian, Latinx, and multirace participants. Trialists should be aware of RCT-level factors and characteristics that may be associated with low participation of racial and ethnic minorities, which could inform evidence-based interventions to increase minority participation.eng
dc.description.sponsorship1187594-09-7; 2349386-89-4; 2492423-29-5; 1809249-37-3
dc.identifier.doi10.1093/epirev/mxae006
dc.identifier.issn1478-6729
dc.identifier.urihttp://hdl.handle.net/10400.1/28812
dc.language.isoeng
dc.peerreviewedyes
dc.publisherOxford University Press (OUP)
dc.relationBioaugmentation and conjugative plasmid transference using bacteria from extreme environments to enhance biodegradation of recalcitrant pollutants in WWTP granular sludge
dc.relation.ispartofEpidemiologic Reviews
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectRandomized controlled trial
dc.subjectCOVID-19
dc.subjectRace
dc.subjectEthnicity
dc.subjectTherapeutics
dc.titleReporting of participant race and ethnicity from COVID-19 randomized controlled drug and biologicals trials: a scoping revieweng
dc.typejournal article
dspace.entity.typePublication
oaire.awardNumberPTDC/CTA-AMB/7782/2020
oaire.awardTitleBioaugmentation and conjugative plasmid transference using bacteria from extreme environments to enhance biodegradation of recalcitrant pollutants in WWTP granular sludge
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/3599-PPCDT/PTDC%2FCTA-AMB%2F7782%2F2020/PT
oaire.citation.endPage14
oaire.citation.issue1
oaire.citation.startPage1
oaire.citation.titleEpidemiologic Reviews
oaire.citation.volume47
oaire.fundingStream3599-PPCDT
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameEstêvão
person.givenNameMaria Dulce da Mota Antunes de Oliveira
person.identifierI-4695-2014
person.identifier.ciencia-id881B-53E8-0DB1
person.identifier.orcid0000-0002-7151-8363
person.identifier.scopus-author-id8381590400
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
relation.isAuthorOfPublication67887883-2695-48cc-8221-aa46780ac143
relation.isAuthorOfPublication.latestForDiscovery67887883-2695-48cc-8221-aa46780ac143
relation.isProjectOfPublication0b09c039-bd11-41d7-bebf-ae11435c521d
relation.isProjectOfPublication.latestForDiscovery0b09c039-bd11-41d7-bebf-ae11435c521d

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
mxae006.pdf
Tamanho:
1.28 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
3.46 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

ESS2-Artigos (em revistas ou actas indexadas)